


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Previously Presented) A compound of formula I



wherein

R^1 is H, OH, OA, CN, Hal, COR or CH_2R ,

R is by OH, OA, NH_2 , NHA or NA_2 ,

R^2 and R^3 are H or A,

A is an alkyl group with 1–10 atoms,

X is O or S,

Hal is F, Cl, Br or I

n is 2-6,

m is 1-4

p is 0, 1, 2, 3 or 4

or a salt, enantiomer, solvate, racemate or mixture of enantiomers thereof.


Claim 2. (Previously Presented) A compound according to claim 1, wherein R¹ is F or CN.

Claim 3. (Previously Presented) A compound according to claim 1, wherein R³ is H.


Claim 4. (Canceled)

Claim 5. (Canceled)


Claim 6. (Previously Presented) A compound according to claim 1 of the formula I1 to I5:




I1




I2



I3



I4



I5

or a salt, solvate, enantiomer or racemate thereof.

Claim 7. (Previously Presented) A pharmaceutical composition comprising a formula I according to Claim 1 or physiologically acceptable salt or solvate thereof and a pharmaceutically acceptable carrier.

Claims 8. – 14. (Canceled)

Claim 15. (Currently Amended) A method for the treatment of cerebral stroke, cerebral ischaemia, overexcitation, hyperactivity, attention disorder, deep-seated development disorder, mental retardation, depression, compulsive disorder, sleep disorders, sexual disorders, eating disorders, senile dementia or Alzheimer's dementia, schizophrenia, or for the control of psychotic anxiety states, comprising administering to a host in need thereof a compound according to claim 1 or a salt, solvate, enantiomer or mixture thereof.